Holen Sie sich die Stockscreener-App
0.9018
2.32%
-0.0214
Schlusskurs vom Vortag:
$0.9232
Offen:
$0.89
24-Stunden-Volumen:
47,930
Relative Volume:
0.56
Marktkapitalisierung:
$39.94M
Einnahmen:
$15.97M
Nettoeinkommen (Verlust:
$-24.40M
KGV:
-1.1889
EPS:
-0.7585
Netto-Cashflow:
$-45.82M
1W Leistung:
+4.82%
1M Leistung:
-3.04%
6M Leistung:
-16.50%
1J Leistung:
-57.46%
1-Tages-Spanne:
$0.89
$0.9499
1-Wochen-Bereich:
$0.86
$1.00
52-Wochen-Spanne:
$0.50
$2.50
Elutia Inc Stock (ELUT) Company Profile
Firmenname
Elutia Inc
Sektor
Branche
Telefon
240-247-1143
Adresse
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
0.9018 | 40.89M | 15.97M | -24.40M | -45.82M | -0.7585 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-02 | Eingeleitet | Cowen | Outperform |
| 2020-11-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-11-02 | Eingeleitet | Truist | Buy |
Elutia Inc Aktie (ELUT) Neueste Nachrichten
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch - Sahm
Cellution Biologics Acquires SimpliDerm From Elutia for Up to $11 Million - citybiz
ELUT Looks 5.6% Overvalued on GF Value™ - GuruFocus
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. - The Manila Times
Elutia Flat on Sale to Cellution - Baystreet.ca
Elutia sells SimpliDerm business for up to $11 million - Investing.com
Elutia sells SimpliDerm business for up to $11 million By Investing.com - Investing.com India
Elutia gets $8 million at closing as FDA clearance is expected in 2027 - Stock Titan
SILVERARC CAPITAL MANAGEMENT, LLC Trims Elutia Inc (ELUT) Stake -- Shares Look 11% Overvalued on GF Value - GuruFocus
Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. - marketscreener.com
Elutia (ELUT) Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Advance 1.49%Earnings Outlook Update - Vinanet
Elutia Inc (ELUT) Stock News Today - TradingKey
Elutia Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ELUT) 2026-08-16 - Seeking Alpha
Downgrade: What You Need To Know About The Latest Elutia Inc. (NASDAQ:ELUT) Forecasts - simplywall.st
Elutia secures $26M to launch NXT-41x, targetin... - Pluang
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results - Sahm
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com Australia
Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares - Stock Titan
Elutia Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic - GuruFocus
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ... By GuruFocus - Investing.com Canada
ELUT Looks 2.2% Undervalued on GF Value™ Amid Challenging Sales and Cash Flow - GuruFocus
Elutia Inc. (NASDAQ: ELUT) Share Price, ELUT Stock News, ELUT Share Price & Updates - kalkine.ca
Earnings call transcript: Elutia Q2 2026 revenue miss offset by margin gains - Investing.com Nigeria
ELUT: Q2 delivered improved margins, strong funding, and high surgeon demand for NXT-41x - TradingView
Elutia secures $26M in capital, expects FDA decision on NXT-41 - Investing.com Australia
Elutia Q2 2026 Earnings Call Transcript - Benzinga
ELUT: Improved margins, strong funding, and high surgeon demand set up NXT-41x for 2028 launch - TradingView
Elutia Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Elutia Inc. Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41X Launch in $1.5 Billion Plastic and Reconstructive Surgery Market - marketscreener.com
Elutia secures $15 million financing for product development By Investing.com - Investing.com Nigeria
Elutia Inc. (ELUT) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Is Elutia Inc (ELUT) Positioned for Growth After Q2 Earnings? EPS at -$0.15, Revenue at $2.90M -- GF Score: 34/100 - GuruFocus
Elutia Secures $15 Million Loan Financing From Avenue Capital Group - TradingView
Elutia secures $15 million financing for product development - Investing.com
Elutia Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Elutia 2Q Sales $2.43M >ELUT - Moomoo
Elutia's Biomatrix Targets 15–20% Infection Rates in Plastic Surgery - Stock Titan
96% of Plastic Surgeons Interested in Elutia’s NXT-41x - Stock Titan
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market - marketscreener.com
Earnings To Watch: Elutia Inc (ELUT) Q2 2026 -- GF Value Sees 6% Downside - Yahoo Finance
Elutia Inc expected to post a loss of 15 cents a shareEarnings Preview - tradingview.com
Elutia Inc. (ELUT) stake of 2.19M shares reported by SilverArc - Stock Titan
Elutia Inc. (ELUT) Slips 1.47% to $0.80 as Stock Holds Above Key Support ZoneElliott Wave Entry - Vinanet
Elutia | 8-K: Current report - Moomoo
Elutia Receives Nasdaq Notice on Listing Compliance Risk - The Globe and Mail
Elutia Inc (ELUT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Elutia | 4: Statement of changes in beneficial ownership of securities-Director Makes Brigid - Moomoo
Elutia Inc. (ELUT) Files Form 8-K: Nasdaq-Listed Delaware Biologics Company Updates Corporate Information - Minichart
Earnings Preview: Elutia to Report Financial Results Post-market on August 13 - Moomoo
Elutia Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Finanzdaten der Elutia Inc-Aktie (ELUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):